Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with a directed share issue (3)
Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

October 23, 2020 Capital Markets and Public M&A

Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives gross proceeds of approximately SEK 265 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is inter alia to enhance the company’s financial position ahead of negotiating a deal pertaining to its lead product HyNap-Dasa and to continue to expand the company’s product portfolio.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström, Joel Magnusson and Linnea Petersson.

Related

Vinge has advised VAROPreem in connection with its acquisition of Sunpine

 Vinge has advised VAROPreem in connection with its acquisition of Sunpine from Sveaskog, Södra Skogsägarna and Lawter.
July 10, 2026

Vinge advises Consolid Equity in connection with the establishment of Petra Group

 Vinge has advised Consolid Equity Investment AB ("Consolid Equity") on the acquisition of Ström & Gulliksson, one of the leading patent agencies in the Nordics. The acquisition forms part of the establishment of Petra Group, a European platform aimed at consolidating patent agencies across Europe to combine expertise and resources primarily within patents and trademarks. Consolid acts as a strategic partner in the new group.
July 08, 2026

Vinge has advised Scandic on new credit facilities with SEK 7.5 billion credit facilities

 Vinge has represented Scandic Hotels Group AB (publ) in connection with a facilities agreement for SEK 7,500,000,000 with a syndicate of banks, arranged by DNB Carnegie Investment Bank AB and Nordea Bank Abp, filial i Sverige.
July 08, 2026